Bone Marrow Stromal Cells
Bone Marrow Stromal Cells (BMSCs), also known as mesenchymal stem cells (MSCs), are multipotent stem cells found in the bone marrow that support hematopoiesis and contribute to tissue regeneration. BMSCs can differentiate into bone, cartilage, fat, and muscle cells, making them valuable for regenerative medicine. They play a crucial role in immunomodulation, reducing inflammation, and promoting wound healing. BMSCs are widely studied for treating osteoarthritis, bone fractures, autoimmune diseases, and neurological disorders. Their ability to secrete growth factors and support angiogenesis enhances their therapeutic potential. However, challenges like donor variability and long-term safety remain areas of ongoing research.
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells (iPSCs) are reprogrammed adult cells that exhibit properties similar to embryonic stem cells, capable of differentiating into various cell types. First developed in 2006, iPSCs revolutionized regenerative medicine by offering patient-specific therapies without ethical concerns associated with embryonic stem cells. They hold immense potential for disease modeling, drug testing, and cell-based therapies for conditions like neurodegenerative diseases, diabetes, and cardiovascular disorders. Advances in gene editing, particularly CRISPR, enhance iPSC applications in personalized medicine. Despite challenges such as tumorigenicity and differentiation efficiency, iPSCs remain a cornerstone of modern regenerative medicine and biomedical research.
Single-Cell Sequencing
Single-Cell Sequencing (SCS) is a powerful technology that enables the analysis of individual stem cells at a genomic, transcriptomic, and epigenetic level. It provides deep insights into stem cell heterogeneity, differentiation pathways, and cellular responses to environmental cues. In regenerative medicine, SCS helps identify rare stem cell subpopulations, track lineage development, and optimize cell therapies. It is crucial for understanding mechanisms underlying tissue regeneration, disease progression, and aging. Combined with artificial intelligence and CRISPR gene editing, SCS accelerates precision medicine by improving stem cell-based treatments for neurodegenerative diseases, cancer, and organ regeneration while reducing risks like tumorigenicity.
Autologous vs. Allogeneic Stem Cell Therapies
Autologous vs. Allogeneic Stem Cell Therapies differ in their source and application. Autologous stem cell therapy uses a patient’s own stem cells, reducing the risk of immune rejection and graft-versus-host disease (GVHD). It is widely used in regenerative medicine and personalized treatments for conditions like leukemia and orthopedic injuries. Allogeneic stem cell therapy, on the other hand, utilizes stem cells from a donor, offering an off-the-shelf solution for large-scale treatments. While it allows for mass production and standardized therapies, it carries risks of immune rejection. Both approaches have distinct advantages and are crucial in advancing stem cell-based treatments.
Tissue Engineering & Biomaterials
Tissue Engineering & Biomaterials are transforming regenerative medicine by enabling the creation of functional tissues for repair and transplantation. Tissue engineering combines stem cells, biomaterials, and bioactive molecules to regenerate damaged tissues and organs. Biomaterials, including natural (collagen, fibrin) and synthetic (polymers, hydrogels) materials, provide structural support and mimic the extracellular matrix to enhance cell growth and differentiation. Advances in 3D bioprinting and scaffold technology allow for precise tissue fabrication, improving treatments for bone defects, cartilage injuries, and organ regeneration. Despite progress, challenges like vascularization, immune response, and long-term integration remain critical for clinical applications of engineered tissues.
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation (HSCT) is a life-saving procedure used to treat blood disorders, immune deficiencies, and cancers like leukemia and lymphoma. It involves replacing damaged or diseased hematopoietic stem cells (HSCs) with healthy ones from a donor (allogeneic HSCT) or the patient’s own cells (autologous HSCT). These stem cells, primarily sourced from bone marrow, peripheral blood, or umbilical cord blood, regenerate the blood and immune system. HSCT is crucial for conditions like aplastic anemia and sickle cell disease. While it offers curative potential, challenges such as graft-versus-host disease (GVHD), infection risk, and donor matching remain key concerns.
Gene Editing in Stem Cells
Gene Editing in Stem Cells is revolutionizing regenerative medicine by enabling precise modifications to the genome for disease treatment and research. Technologies like CRISPR-Cas9, TALENs, and ZFNs allow scientists to correct genetic mutations in stem cells, enhancing their therapeutic potential. Induced pluripotent stem cells (iPSCs) combined with gene editing are used to model diseases, develop personalized treatments, and create genetically corrected cells for transplantation. This approach shows promise for genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy. However, challenges such as off-target effects, ethical concerns, and long-term safety must be addressed for clinical applications.
Stem Cells in Disease Modeling
Stem Cells in Disease Modeling play a crucial role in understanding disease mechanisms, drug discovery, and personalized medicine. Induced pluripotent stem cells (iPSCs) enable scientists to create patient-specific models for conditions like neurodegenerative diseases, cardiovascular disorders, and genetic syndromes. By differentiating stem cells into affected cell types, researchers can study disease progression, identify biomarkers, and test potential treatments in a controlled environment. Organoids, 3D mini-tissues derived from stem cells, further enhance disease modeling by mimicking complex organ structures. Stem cell-based models accelerate precision medicine, reduce reliance on animal testing, and improve the development of targeted therapies for various diseases.
Stem Cells in Musculoskeletal Regeneration
Stem cells, particularly mesenchymal stem cells (MSCs), are being studied for their ability to regenerate musculoskeletal tissues, such as cartilage, bone, and tendons. These therapies have the potential to treat conditions like osteoarthritis, fractures, and sports injuries by promoting tissue repair and regeneration.
- Stem cells in muscle regeneration and sports medicine
- Stem cells for bone and cartilage regeneration
Infectious Disease and Tissue Repair
Stem cells play a vital role in tissue repair following infections by regenerating damaged tissues and modulating immune responses. They hold potential for treating diseases like COVID-19, where lung tissue regeneration and immune modulation are crucial for recovery.
- Stem cells in the treatment of viral and bacterial infections
- Stem cells in the repair of damage caused by sepsis
Clinical Trials and Stem Cell Therapies
Clinical trials are increasingly exploring stem cell-based therapies for a range of diseases, including neurodegenerative conditions, cardiovascular diseases, and cancers. These trials are crucial for evaluating the safety, efficacy, and potential of stem cell treatments, paving the way for future therapeutic breakthroughs.
- Challenges in the clinical translation of stem cell therapies
- Future directions for clinical applications and commercial therapies
Stem Cells in Cancer Research
Stem cells are being used to study cancer stem cells (CSCs) and tumor behavior, allowing for more precise models of cancer progression. Stem cell-based therapies also hold promise in targeting CSCs directly, offering potential solutions to prevent relapse and metastasis in cancer patients.
- Characteristics and therapeutic potential
- Stem Cells for Tumor Immunity and Regeneration
Stem Cells in the Treatment of Genetic Disorders
Stem cell therapies hold promise for treating genetic disorders by replacing damaged or defective cells with healthy ones. Techniques like gene editing, combined with stem cells, offer potential cures for conditions like sickle cell anemia, cystic fibrosis, and muscular dystrophy, by addressing the root genetic cause.
- Gene therapy and stem cells in the treatment of inherited diseases
- Ethical challenges and clinical application of genetic modification in stem cell
Latest News
Scientists steer the development of stem cells to regenerate and repair organs
2024-12-20 - 2024-12
Investigators from Cedars-Sinai and the University of California, San Francisco (UCSF) have identified a new way to deliver instructions that tell stem cells to grow into specific bodily structures, a critical step in eventually regenerating and repairing tissues and organs.
The scientists engineered cells that form structures called "synthetic organizers." These organizers provided instructions to the stem cells through biochemical signals called morphogens, which stimulated and enabled the stem cells to grow into specific complex tissues and organ-like assemblies.
The research was conducted with mouse embryonic stem cells, and the findings were published in Cell.
"We can use these synthetic organizers to push the stem cells toward making different parts of the early embryo or toward making a heart or other organs," said Ophir Klein, MD, Ph.D., co-corresponding author of the study, executive vice dean of Children's Health and executive director of Cedars-Sinai Guerin Children's.
In one instance, scientists were able to induce the stem cells to begin to form a mouse body that stretched from head to tail, similar to regular embryonic development in the womb. In another instance, the scientists were able to spur the stem cells to generate a large heart-like structure complete with a central chamber and a regular beat, along with a network of early blood vessels.
"This type of synthetic organizer cell platform provides a new way to interface with stem cells and to program what they develop into," said Wendell Lim, Ph.D., co-corresponding author and professor of Cellular and Molecular Pharmacology at UCSF.
"By controlling and reshaping how stem cells differentiate and develop, it might allow us to grow better organs for transplantation or organoids for disease modeling and eventually utilize it to drive tissue regeneration in living patients."
To steer organizer cells and control stem cell development, the scientists uploaded genetic codes into the cells and engineered two key features in the cells.
First, they instructed the cells to stick to the stem cells in the form of a node or a shell clustering around the clump of stem cells. Second, the investigators engineered the organizer cells to produce specific biochemical signals crucial to inducing early embryonic development.
To effectively and precisely control the organizer cells, researchers developed a chemical switch within the cells, allowing scientists to turn the delivery of instructions to stem cells on or off. Additionally, they installed a "suicide" switch to eliminate the organizer cells when needed.
"These synthetic organizers show that we can provide more refined developmental instructions to stem cells by engineering where and when specific morphogen signals are provided," Lim said. "The organizer cells carry both spatial information and biochemical information, thus giving us an incredible amount of control that we have not had before."
Stem cells head to the clinic: treatments for cancer, diabetes and Parkinson’s disease could soon be here
2024-12-20 - 2024-12
The study is one of more than 100 clinical trials exploring the potential of stem cells to replace or supplement tissues in debilitating or life-threatening diseases, including cancer, diabetes, epilepsy, heart failure and some eye diseases. It’s a different approach from the unapproved therapies peddled by many shady clinics, which use types of stem cell that do not turn into new tissue.
All the trials are small and focus mainly on safety. And there are still substantial challenges, including defining which cells will be most fit for which purposes and working out how to bypass the need for immunosuppressant drugs that stop the body from rejecting the cells but increase the risk of infections.
Still, the flurry of clinical studies marks a turning point for stem-cell therapies. Following decades of intense research that has at times triggered ethical and political controversy, the safety and potential of stem cells for tissue regeneration is now being widely tested. “The rate of progress has been remarkable,” says stem-cell specialist Martin Pera at the Jackson Laboratory in Bar Harbor, Maine. “It’s just 26 years since we first learnt to culture human stem cells in flasks.”
Researchers expect some stem-cell therapies to enter the clinic soon. Treatments for some conditions, they say, could become part of general medicine in five to ten years.
Finding a source
Cassy’s symptoms began with a small, persistent tremor in his fingers when he was just 44. The characteristic motor symptoms of Parkinson’s are driven by the degeneration of dopamine-producing neurons called A9 cells in the brain’s substantia nigra. Drugs that replace the missing dopamine are effective, but have side effects including uncontrolled movements and impulsive behaviors. And as the disease progresses, the drugs’ efficacy wanes and the side effects worsen.
The idea of replacing the degenerated dopaminergic cells has a long history. During development, pluripotent ES cells, which have the potential to become many cell types, turn into the specialized cells of the brain, heart, lungs and so on. Theoretically, transplanted stem cells could repair any damaged tissue.
Parkinson’s lent itself to testing that theory. The first transplant of such cells took place in Sweden in 1987 using neurons from the developing brains of fetuses from terminated pregnancies, the only source of immature, or progenitor, neural cells at the time. Since then, more than 400 people with Parkinson’s have received such a transplant — with mixed results. Many people saw no benefit at all, or had debilitating side effects. But others improved so much that they no longer needed to take dopaminergic drugs.
Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine
2024-12-27 - 2024-12
Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine
SINGAPORE - Media Outreach Newswire - 27 December 2024 - Black Group Investment Holding Pte Ltd (Black Group) and Zenzic Oasis Holding Pte Ltd (Zenzic Oasis) today announced that they have signed an investment and strategic partnership agreement with the goal of expanding the use of cell-based therapeutic solutions, including personalised treatments.
Under the terms of the agreement, Black Group Investment Holding will invest in the commercialisation of Zenzic Oasis’ stem cell technologies, including induced pluripotent stem cells (iPSCs). Dr. Lim Kah Meng, the founder of Zenzic Oasis, is widely recognised for his breakthrough research on placental stem cells, which has led to the development of highly sought-after commercial products in the field of regenerative medicine. The partnership will further advance the commercialisation of these stem cell therapies by leveraging Black Group’s regional distribution networks and hospitality expertise.
Both companies will work together to bring these innovative stem cell-based products to regional markets, with a focus on personalised treatments.
Black Group will oversee the scaling, manufacturing, and distribution of stem cell therapies, ensuring accessibility and quality control of the products through a broadly accessible channel. “We are excited to partner with Black Group to accelerate the commercialisation of our stem cell-based innovations,“ said Dr. Lim Kah Meng. “This partnership will allow us to bring life-changing therapies (via clinical or validation trials) or wellness solutions to patients suffering from some of the most challenging medical conditions, and improving lives through personalised medicine.”
Black Group Investment Partners with Zenzic Oasis to Advance Stem Cell Therapy for Personalised Medicine
'It was so easy to give people more years of life'
2024-12-28 - 2024-12
A man has given his stem cells twice in the space of a decade to help save the lives of two people.Brad Green, from Sheffield, was inspired to sign the Anthony Nolan stem cell register at the age of 20 after a school friend's dad was diagnosed with leukaemia.
Mr Green said he did not expect being called to donate just two weeks later and was even more surprised when he was told he was a match for a second person earlier this year.
He is now one of 0.7% of donors to have given his stem cells twice.
Speaking of his first experience, Mr Green, now 31, said he remembered thinking: "God, how easy was that?""Because it's anonymous and because you don't really see the impact it's having first hand, you're sitting there thinking, 'well, I've done my bit, now I can go home'," the father-of-one said.
"But actually, at that point, it's that patient's start of his journey to recovery."
Mr Green initially did not know who had received his stem cells but later learned the patient was John Herries, who had been diagnosed with an aggressive type of blood cancer.
The pair eventually went on to meet and to this day keep in touch via email.Mr Herries, who is 59 and a beach lifeguard from north Devon, said: "It was a real pleasure to meet Brad and his parents."We're genetic twins so it was interesting to see if we looked the same – we didn't."The Anthony Nolan charity supports people with blood cancer and blood disorders. The register was established in 1974.Earlier this year, nearly a decade after his first donation, Mr Green received another call from the charity telling him he was a match for a second person.
Donors in the UK can only give stem cells twice to two different patients, though Mr Green said if he could, he would continue to donate."For me, it was just so easy for what you're actually getting in return, which is potentially giving somebody a load more years of life with family and friends," he said."I can't do it a third time, but I would do it three, four, five times over if it was possible."Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North or tell us a story you think we should be covering here.
Indian American Doctors Organisation Spearheads Stem Cell Registration Drive
2024-12-30 - 2024-12
He American Association of Physicians of Indian Origin (AAPI), a non-profit organization that represents over 35,000 Indian American physicians, has started an initiative for bone marrow and stem cell registration across the US. AAPI has partnered with America’s National Marrow Donor Program (NMDP) to increase the Indian donor pool.
“Patients with leukaemia and lymphoma need bone marrow or blood stem cell transplant to survive. Finding matching donors for cancer patients are difficult, especially for those of Indian and South Asian ethnicity. This drive, in which dozens of local AAPI chapter leaders, members and volunteers across the US have participated, is to increase the limited pool of donors and create awareness among more youth and adults to enrol,” Dr Satheesh Kathula, an oncologist based in Dayton, Ohio and the president of AAPI for the 2024-2025 term, told the Times of India.
“In the US, about 25% of the doctors are immigrants and of that number the majority are Indian Americans. Indian American physicians hold key positions not just in healthcare but also in research, academia and administration. Many serve in critical positions in underserved areas,” Dr Kathula, who has is a recipient of the US Presidential Lifetime Achievement Award for 2023-2024, said.
Started over four decades back, to fight discrimination against foreign doctors, in granting licences, by some US states, AAPI has emerged a prominent professional organisation working as a social, educational, political and advocacy platform for Indian American doctors, Dr Kathula said. The AAPI Young Physicians section and AAPI Medical Students, Residents and Fellows section are focussed on Indian American medical and dental students, residents and fellows, and physicians-in-training. “We support and encourage the younger generation of Indian American doctors in many ways including communication, legislation, collaboration and education. Addressing the increasing shortage of physicians, we are trying to increase recruitment and encouraging more younger generation members to join our organisation. We provide opportunities for students, including those coming from India, to present research papers and have also been advocating for legislative reforms to ease the residency pathway for international medical graduates,” Dr Kathula said.
While AAPI is committed to promoting medical education and supporting young physicians’ knowledge base through continuing medical education, enhancing their careers, and empowering them to play a key role in healthcare advocacy and community service; the organisation also plays an important role in providing a channel between US law makers and its members. “AAPI advocates for policies that expedite green card processes for doctors on H1 visas,” Dr Kathula said.
He was at the helm in conceptualising and organising the AAPI Global Healthcare Summit in New Delhi last October and feels that the topics that were covered, including prevention strategies f
Stem Cell Donation: Woman's emotion at making 'one-in-800' match
2025-01-01 - 2025-01
When Kilkeel woman Alana Campbell signed up to become a potential stem cell donor she knew the odds of being matched with someone in need were against her.But after her nephew Robin was diagnosed with a rare genetic disorder almost 15 years ago and needed a life saving stem cell transplant, she felt she had to do something.Remarkably, within six months of registering, she was informed she was a "perfect match" for a woman in France.
"I have to say I actually cried. I try not to cry now," she said.
Robin's parents feel very lucky they were able to find a stem cell donor for him when he was three years old and incredibly sick.No-one in the family was a match but they were able to find one a bit further afield."It was an Italian donor, that's all we know. We don't know anything more," said Robin's dad Geoffrey Calvert."We would love to know who he was or anything like that."
But regardless of who he was, they know if he hadn't signed up to be a donor Robin might not be around today. Currently the odds of becoming a match for someone who needs a stem cell donation is about one-in-800.
Michael Gallagher, from the Blood Cancer Charity DKMS, said it needed more people to register as donors to give others a higher chance of survival."Back in 2019, we saw close to 100,000 people register with us and now we're getting half of that," she said.He said each year there were hundreds of people across the UK who were told there was no match for them. Now that Alana has seen stem cell donation from both sides she is passionate about getting others to sign up.She remembers the day she made her donation and there was someone waiting "with one of those little suitcases you take on the plane".She said it was like something out of a film.All she ever knew was that the woman she helped was in her 50s and very ill.She got a phone call the following year telling her she was still alive."It was a very emotional journey. I would do it again tomorrow," she said.
Scientists Have Grown a Human Spine in a Lab
2025-01-03 - 2025-01
Scientists have officially grown a notochord—the tissues that act as the “GPS for the developing embryo” by guiding the formation of the spine and nervous system. Previous attempts to create a notochord from human stem cells have failed because scientists didn’t have a firm grasp on the ideal timing of the introduction of certain biological “ingredients” to spur growth. Now that they have grown a notochord—albeit a simple one—the researchers hope this lab-grown spinal tissue will give us insights into spine-related birth defects and other intervertebral discs (the cushy tissue that lies between our vertebrae).When people say “grow a backbone,” they usually don’t mean it literally. But scientists at The Francis Crick Institute in London recently took the challenge to heart and successfully developed human stem cells models with notochord tissue. During the development of an embryo, this rod-like tissue acts as a kind of crucial scaffold, and helps dictate where cells should build out the spine and nervous system.
This is the first stem cell model to contain a notochord, which is a big deal, considering their central role in early embryonic development. The results of the study were published earlier this week in the journal The notochord acts like a GPS for the developing embryo, helping to establish the body’s main axis and guiding the formation of the spine and nervous system,” James Briscoe, senior author of the study, said in a press statement. “Until now, it’s been difficult to generate this vital tissue in the lab, limiting our ability to study human development and disorders.” In order to create this human notochord, the scientists had to rely on some help from our fellow vertebrate friends. First, they analysed chicken embryos, and compared them to mice and monkeys—animals closer to our particular branch on the tree of life. With this information, the researchers could develop the timing and sequence of molecular signals needed to create a stem cell model with notochord tissue. Because this is a stem cell model rather than a full-blown embryo, the cells (according to the researchers) create a “trunk-like structure” that extends 1 to 2 millimetres in length. Although not the most substantial of spines, this minuscule structure crucially contained all of the neural tissues and bone stem cells correctly arranged in a pattern just like those found in human embryos.
1st stem cell therapy, new HIV drug approved
2025-01-04 - 2025-01
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only requires two shots yearly.The National Medical Products Administration said on Thursday that it granted conditional approval to an injection from the domestic drugmaker Platinum Life to treat patients aged 14 and above who suffer a rare disease called acute graft-versus-host disease and do not respond to regular steroid therapy.
Acute graft-versus-host disease, or aGVHD, typically hits patients who have just undergone a stem cell transplant due to severe blood condition. The disease is one of the primary reasons for death following transplantation.The homegrown therapy is the first mesenchymal stromal cell treatment that has gained the green light on the Chinese mainland. The approval was issued through an accelerated market registration track designed for novel or urgently needed medicines.Stem cell therapy utilizes the differentiation and self-renewal capacity of stem cells to repair tissues and treat diseases. It represents a booming research field being studied worldwide to treat a variety of illnesses, including diabetes, Parkinson's disease and cancer.
In China, the nation's first drug manufacturing license for stem cell treatment was issued in late May by the Beijing Municipal Medical Products Administration to Platinum Life.Chen Jiekai, a researcher at the Chinese Academy of Sciences' Guangzhou Institutes of Biomedicine and Health, said that the issue of the license constitutes a key step toward clinical applications of stem cell treatment and signals the establishment of a complete supervision procedure for this kind of novel therapy.During an academic conference held in Guangzhou, Guangdong province in early December, he said that there are hundreds of clinical research projects on stem cell treatment across the nation and a total of 141 hospitals have registered with a national medical research platform in preparation for carrying out stem cell clinical studies, local media reported.Also on Thursday, China approved lenacapavir, a long-acting HIV drug made by global biopharmaceutical company Gilead Sciences, according to the administration and the company.The treatment is approved to treat HIV patients who have multidrug resistance and cannot have their viral load effectively suppressed under available drug regimens.It was first approved in Europe and the United States in 2022 and research is underway to test its potential in preventing infection
Applications of artificial intelligence in regenerative dentistry: promoting stem cell therapy and the scaffold development
2025-01-05 - 2025-01
Tissue repair represents a critical concern within the domain of dentistry. On a daily basis, countless individuals seek dental clinic services due to inadequate dental care. Many of the treatments that patients receive have unfavorable side effects. The employment of innovative methodologies, including gene therapy, tissue engineering, and stem cell (SCs) applications for regenerative purposes, has garnered significant interest over the past years. In recent times, artificial intelligence, particularly neural networks, has emerged as a topic of considerable attention among many medical professionals. Artificial intelligence possesses the capability to analyze data patterns through learning algorithms. Research opportunities in the rapidly expanding field of health sciences have been made possible by the use of artificial intelligence (AI) technologies. Though its uses are not restricted to these situations, artificial intelligence (AI) has the potential to improve and accelerate many aspects of regenerative medicine research and development, especially when working with complicated patterns. This review article is to investigate how artificial intelligence might be used to enhance regenerative processes in dentistry by using scaffolds and stem cells, in light of the continuous advances in artificial intelligence in the fields of medicine and tissue regeneration. It highlights the difficulties that still exist in this developing sector and explores the possible uses of AI with a particular emphasis on dentistry practices.
Introduction:
Recently, AI has grown in a number of ways thanks to developments in needs of computer hardware, software, and algorithms. Artificial intelligence is a field of computer science that lets machines work and solve problems in the same way as people do. Due to the feasibility of mimicking cognitive functions and tidning error experiences for performance enhancement; this technology has risen in popularity in the medical and dental sectors (Bays et al., 2023; Nelson et al., 2020). Advancements in other subsections of AI like machine learning (ML), deep learning (DL), and natural language processing (NLP) have enhanced the possible uses of AI in delivering efficient diagnostic, therapeutic and regenerative medicine solutions (Lauriola et al., 2022). ML being a subcategory of AI uses coded data and comes up with improved patterns out of the results it produces by learning from the mistakes it makes through iterative changes (Alam, 2021; Kaul et al., 2020). A subcategory of ML, deep learning applies artificial neural networks based on human cortical ones, including their connections and functions as carries and processors of information (Liu et al., 2020; Qayyum et al., 2020). DL uses artificial neural networks, which are based on the structure of neurons, and data processing occurs in layers, working with data in numeric form to conduct analyses on large and various datasets. This makes it possible for DL algorithms to
India needs stem cell donor registry
2025-01-07 - 2025-01
Childhood cancer remains a significant global health challenge, with over three lakh new cases reported annually. India contributes more than 50,000 of these cases, placing it among the countries with the highest burden. Leukaemia, the most common childhood cancer in India, accounts for about 30% of cases.
Adding to this burden is thalassemia, which impacts approximately 10% of global cases. These diseases, along with other conditions like sickle cell disease, bone marrow failure, primary immune deficiency disorders, and rare metabolic disorders represent a burden of diseases that require advanced treatment options.Over the years, medical advancements have introduced transformative therapies, and one of the most impactful among them is stem cell therapy.
Stem cell therapy, also known as bone marrow transplantation (BMT), offers a life-saving treatment option. This procedure replaces diseased or damaged cells with healthy stem cells, restoring the body’s ability to produce blood cells. With survival rates exceeding 90% for transplants performed using fully matched sibling donors, BMT stands as one of the most effective cures available. However, the success of stem cell transplants depends on finding compatible donors, which is a significant challenge.
Challenges
India requires approximately one lakh transplants annually, yet only around 2,000 are performed due to the limited availability of compatible donors. One of the primary challenges contributing to this shortage is the low number of registered donors. India has only six lakh registered donors, and the chances of finding a match are low. Only 30% of patients find donors within their families, leaving the rest reliant on unrelated donors from registries, a resource India severely needs to improve.
Automated iPS cell production to start in Japan in April
2025-01-08 - 2025-01
KYOTO –
Following its success in automating the process of creating induced pluripotent stem cells, Kyoto University's CiRA Foundation will start producing iPS cells from patients' own cells utilizing the automated culture system in April.
Under a project aimed at making iPS cells — which theoretically can develop into almost all organs — widely available for regenerative medicine by drastically reducing the production cost, the foundation has successfully created the stem cells in a month using a German-made immune cell production apparatus in which a healthy person's blood, reagents and specific genes were mixed.
From April, the foundation will automatically make autologous iPS cells and turn them into, among others, heart muscle and nerve cells at a new facility in the city of Osaka. The iPS cell-derived cells will be frozen with liquid nitrogen and stored for later safety and efficacy studies.
Immune rejection-free cell transplantation therapies are made possible by the use of autologous iPS cells, which the foundation calls "my iPS cells." But it takes about six months and costs some ¥50 million ($316,000) to manually create iPS cells from a patient's own cells and differentiate them into a specific cell type to treat the patient's disease.
For the time being, the new facility, Uehiro Laboratory for my iPS Cell Research, will be equipped with four units of the German system and produce enough cells for 20 people a year.
But it plans to have 200 units of automated production equipment in total in a decade by developing Japanese-made systems jointly with Canon and Panasonic so it can expand the cell supply capacity to 1,000 people while cutting the production cost to ¥1 million per patient.
"We hope to increase treatment options by making rejection-free autologous cell therapies available to many patients," said Masayoshi Tsukahara, the foundation's research and development chief.
Adam Devine is putting his health first — from trying stem cell treatments to shedding 30 pounds
2025-01-09 - 2025-01
From starring in the Pitch Perfect franchise to entertaining audiences as a stand-up comedian, Adam Devine is a pro at making people laugh. But fans of the funnyman might not realize that Devine has battled health challenges stemming from a terrifying childhood accident in which he was struck by a cement truck. These struggles came to a head about three years ago.
“I just started having all kinds of pain and weird spasms, and at one point, the doctors told me that I had stiff-person syndrome,” the Workaholics star tells Yahoo Life. “So, I thought I was dying right before my son was born, and [later] I found out I don't have stiff-person syndrome, and they couldn't figure it out, and they finally just landed on 'your childhood accident has finally caught up to you.'”
Now, Devine is laser-focused on his well-being, going to physical therapy three times a week and undergoing bodywork — which can include acupuncture treatments and chiropractic therapy — twice a week in addition to “stretching all day long.” He's even traveled to Medellin, Colombia, for stem cell therapy. Along the way, he's learned a lot about what it means to put your health first. Here's what we can learn from him.
Be willing to go the distance for your health
Devine says his pain got so bad for a while that he could hardly walk or stand. “I was on a trip to New York about this time last year for my podcast, This Is Important," he recalls. “We went on a podcast tour, and my guys, Blake [Anderson], Anders [Holm] and Kyle [Newacheck] from Workaholics were like, ‘Let's walk here.’ And I tried, and I walked a block, and I'm like, ‘I'm gonna catch a cab.’ And it was only three blocks away. So I caught a cab, and the cab driver was like, ‘No, what are you doing? Just walk.’ And I'm like, ‘I can't, man.That's a moment Devine can’t help but think of when he explains why he made the trip to South America to undergo stem cell therapy to treat his pain. “I had a few friends that have done it, and I had my doctors look into it, because I didn't know anything about stem cells,” says the actor. “They were like, ‘On the record, we don't do that here in the States. I can't say that you should do it, but off the record, if I were you, I would take advantage of this opportunity and go do it.’ So I went to this clinic called BioXcellerator and did the stem cells.It’s been about two months since his treatment, and Devine is already feeling a little better. “I’m able to hold my son a little longer,” he says. “I'm able to take longer walks. I'm able to stand a little longer.Sometimes you need to change tack After putting on extra weight during his wife Chloe Bridges’s pregnancy, Devine, who recently partnered with MyFitnessPal, set out to lose 30 pounds. But he soon learned that exercise alone was no longer enough to get his 41-year-old body back on track.
“We were arguing over what's the better pizza — Pizza Hut or Domino's — and I’m like, ‘Let’s get both, and then let’s also get Papa John
Youthful Brain Stem Cells Linked to Autism and Brain Cancer
2025-01-10 - 2025-01
They made the discovery while taking a broad genomic survey of human brain cells from the first two decades of life. Many brain diseases begin during different stages of development, but until now we haven’t had a comprehensive roadmap for simply understanding healthy brain development,” said Arnold Kriegstein, MD, PhD, professor of neurology at UCSF and co-corresponding author of the paper“Our map highlights the genetic programs behind the growth of the human brain that go awry during specific forms of brain dysfunction.”The study measured gene expression in cells taken from donated brain samples. The researchers kept track of the original location of each cell to help explain how the brain creates connections.
In addition to the discovery of an early stem cell that could explain the genetics of glioblastoma in adulthood, the data contained hints about the origins of autism. The researchers have published the data as a resource for the field to use for understanding a wide range of other brain disorders. Our study paints one of the most detailed pictures of human brain development,” said Li Wang, PhD, postdoctoral researcher in Kriegstein’s laboratory and co-first and co-corresponding author of the paper.
“Theories based on observations in the clinic and laboratory can now be tested against this hard data, and we’re excited to see what else the field can do with it.”Samples reveal a treasure trove Most studies of the developing brain are carried out in animal models, which are at best loose proxies for the human brain. The team, also led by co-first author Cheng Wang, PhD, and co-corresponding author Jingjing Li, PhD, wagered that valuable new insights could be made by studying the human brain itself. They worked with the National Institutes of Health’s NeuroBioBank and local hospitals associated with UCSF to obtain brain samples. These samples, donated from 27 individuals from early life through adolescence, were sent to UCSF and analyzed for gene expression in thousands of individual cells. Gene expression refers to how DNA, stored in chromosomes, is copied into RNA – short-lived genetic messages – which are then used as a template for building proteins. By measuring RNA, the researchers could peer into the behavior of those cells.“RNA degrades quickly, and you need to have very pristine tissue in order to get usable data,” Kriegstein said It was a huge advance for Li and his colleagues to perform such high-resolution genomic tests on this tissue, and we thank the community for supporting such critical research by donating this precious tissue.”The researchers analyzed which parts of each chromosome were available for expressing genes in each cell. They also labeled where each cell had been taken from in the brain. The scientists focused on cells taken from the front and the back of the cerebral cortex, regions that in humans are responsible for learning, memory and language. RNA alone doesn’t tell the entire story of a cell’s behavior,
Open AI Partners with Retro Biosciences to Engineer Stem Cell Proteins with AI
2025-01-20 - 2025-02
At the heart of this project lies a fascinating scientific challenge: transforming adult skin cells into stem cells, a process that has traditionally been highly inefficient. The current success rate hovers below 1%, taking several weeks to complete. OpenAI's new model tackles this problem by redesigning what scientists call Yamanaka factors—specific proteins that trigger this cellular transformation.
Retro Biosciences was founded in 2021 by Joe Betts-LaCroix with a $180 million investment from Sam Altman. The company employs over 60 scientists and runs five discovery programs, including autophagy and in vivo reprogramming. In 2024, Retro partnered with Multiply Labs in an $85 million agreement to automate its cell therapy manufacturing processes, a critical step in scaling treatments for age-related diseases.
OpenAI's approach with GPT-4b micro, differs significantly from Google DeepMind's AlphaFold, focusing instead on protein interactions rather than structural predictions. By training on protein sequences and interaction data, the model proposed modifications to the Yamanaka factors, yielding proteins that preliminary tests show are 50 times more effective at creating stem cells. According to Betts-LaCroix, the model delivered results faster and better than human-led efforts. The technical achievement here is notable. John Hallman, an OpenAI researcher, notes that "Just across the board, the proteins seem better than what the scientists were able to produce by themselves." The AI model suggests bold modifications, sometimes altering up to a third of a protein's amino acids – a scale of change that would be practically impossible to test through traditional laboratory methods.
The implications for medicine could be significant. Harvard University aging researcher Vadim Gladyshev, who consults with Retro, explains the potential impact: "For us, it would be extremely useful. [Skin cells] are easy to reprogram, but other cells are not." This advancement could pave the way for more efficient organ development and cell replacement therapies.
However, the scientific community will need to wait for peer review and publication of the results before drawing definitive conclusions. OpenAI and Retro have committed to releasing their research findings, though the timeline remains unclear. For now, the model itself won't be immediately available for wider use, remaining a demonstration of capability rather than a commercial product.
New dual stem cell therapy developed to treat brain metastasis in patients with non-small cell lung cancer
2025-01-23 - 2025-01
New research highlights the promise of a novel stem cell treatment strategy for leptomeningeal brain metastasis (LBM), a severe form of metastatic brain cancer that spreads to membranes surrounding the brain and spinal cord and occurs in up to 20% of people with cancer. The researchers say their findings in newly developed preclinical models of metastatic non-small cell lung cancer (NSCLC) support pursuing clinical trials for this treatment strategy.
LBM is a severe form of disease that often occurs in those diagnosed with NSCLC, breast cancer and melanoma, and is linked to poor rates of survival, ranging from eight to 10 weeks.
While first-line therapies for cancer such as chemotherapy have been shown to be ineffective in treating LBM, immune checkpoint inhibitors (ICIs) often have more success in treating NSCLC brain metastasis. However, the efficacy of ICIs in treating LBM from NSCLC has been less successful.
To further investigate this, Mass General Brigham scientists first created immune-competent LBM mouse models that mimic LBM in patient settings. To enhance tumor cell killing and modulate the immune tumor environment, scientists explored testing the therapeutic activity of allogeneic dual stem cells releasing oncolytic herpes simplex virus (oHSV) and a single chain variable fragment of anti-PD-1 (scFvPD-1) in the preclinical models.
Dual stem cells releasing oHSV and scFvPD-1 were delivered locally via intrathecal injection, a technique already used in the treatment of other diseases. The team's findings showed that treatment with dual stem cells enhanced therapeutic outcomes by inducing immunogenic cell death, activating anti-tumor T cell signaling, and disrupting oxidative phosphorylation, which in turn made tumors sensitive to cisplatin.
"Our results support that our dual stem cell-based immunotherapy delivered locally can ultimately improve clinical outcome in patients with NSCLC LBM," said corresponding author Khalid Shah, MS, Ph.D., director of the Center for Stem Cell and Translational Immunotherapy (CSTI) and the vice chair of research in the Department of Neurosurgery at Brigham and Women's Hospital.
"Our work continues to build on developing new mechanism-based therapies for difficult to treat tumors in the brain."
UAE launches Stem Cells Research Centre to advance cutting-edge health care
2025-01-27 - 2025-01
A leading UAE university has launched a centre for stem cell research in support of a nationwide effort to advance cutting-edge health care and cement the country's position as a global leader in regenerative medicine.
The Stem Cells Research Centre, established at United Arab Emirates University in Al Ain, has been hailed as a first for the Emirates.
It aims to develop a "new generation" of Emirati scientists to help drive progress in stem cell therapy and enhance patient care. The centre opened on Monday in the presence of Zaki Nusseibeh, cultural adviser to President Sheikh Mohamed and chancellor of the university.
The centre will seek to bolster research into stem cell therapy, boost manufacturing capabilities and establish international partnerships to support the stem cell market in the Middle East, which is expected to grow from $711.8 million in 2024 to $1.3 billion by 2030.
Prof Fatma Al Jasmi, acting dean of the College of Medicine and Health Sciences at United Arab Emirates University, underlined the importance of the centre for the country's expanding health sector.
"The opening of the Stem Cells Research Centre is a significant achievement that reflects the university's vision to promote research innovation and build national capacities in medical sciences," she said. "Through this centre, we aim to prepare a new generation of Emirati scientists capable of offering advanced medical solutions and solidifying the UAE's position as a global leader in regenerative medicine."
The centre will work to develop innovative treatments and support clinical trials through collaborations with domestic and international partners, including the Abu Dhabi Stem Cells Centre.
Stem cell therapy, also referred to as regenerative medicine, involves the use of stem cells to repair or replace damaged and diseased tissues in the body. Stem cells are grown in labs and tailored for specific treatment, such as organ transplants and some types of cancer therapy.
In 2022, the UAE successfully completed a bone-marrow transplant using longer-term cryogenic freezing of healthy cells.
Scientists at the Abu Dhabi Stem Cells Centre are working round the clock to use stem cells for repairing and regenerating organs. The medical complex has set its sights on becoming a regional hub in the treatment of diseases including Type 1 diabetes and end-stage organ failure.
Speaking to The National in 2023, Dr Yendry Ventura, Abu Dhabi Stem Cells Centre chief executive, outlined his vision for the future.
"My ambition is a world in which we don’t have to wait many years for a donor to give me a kidney while I am attached to a machine," he said. "It could mean the end of patients getting as far as organ failure."
'Breakthrough' stem-cell patches stabilized woman's heart as she awaited transplant
2025-01-31 - 2025-01
A woman with a failing heart has been kept alive with the help of a new "breakthrough" stem-cell technology, scientists report.
The 46-year-old woman had experienced a heart attack in 2016 and subsequently developed severe heart failure, in which the heart cannot pump blood efficiently enough to meet the body's needs. The patient was awaiting a heart transplant when she underwent the experimental stem-cell procedure as part of a clinical trial.
During the surgery, the woman's heart was implanted with tiny patches of heart muscle cells, which had been grown from stem cells in a lab. These 10 patches, each comprised of about 400 million heart cells, kept the woman stable until she could receive a heart transplant three months later, according to a paper published Wednesday (Jan. 29) in the journal Nature.
"We now have, for the first time, a laboratory-grown biological transplant available which has the potential to stabilize and strengthen the heart muscle," study co-author Dr. Ingo Kutschka, a heart surgeon at University Medical Center Göttingen in Germany, said in a press conference, Nature News reported.
Related: In a 1st, baby's heart defect successfully treated with injected stem cells
Unlike many other cell types, such as skin cells, heart muscle cells cannot easily regrow or repair themselves if they are damaged by an insult like a heart attack. Such damage to the heart can lead to heart failure, which affects around 6.7 million adults ages 20 and older in the United States, according to the Centers for Disease Control and Prevention (CDC). Heart failure was listed as a contributing or primary cause of death on more than 450,000 death certificates in the U.S. in 2022, the CDC reported.
Over half of people with severe heart failure die within a year unless they receive a heart transplant, but there are limited donor hearts available, Nature News reported.
To supplement these limited heart transplants, scientists have experimented with transplanting heart muscle cells instead. In the new Nature paper, the researchers describe a method of growing heart tissue from stem cells known as induced pluripotent stem cells (iPSCs). Scientists create these stem cells by gathering normal adult cells and then reprogramming them back into a "pluripotent" state, from which they can develop into almost any cell type in the body.
The scientists encouraged these iPSCs to develop into heart muscle cells and connective tissue in the lab; the researchers then mixed the resulting tissue with collagen to create tiny patches that could be implanted onto the surface of the heart.
"The graft is basically outside of the heart," Dr. Jianyi Zhang, an iPSC bioengineering expert at the University of Alabama at Birmingham who was not involved in this study, told Nature. "It's quite a breakthrough."
The scientists first tested similar patches on rhesus macaque monkeys (Macaca mulatta) with heart failure; the patches tested on monkeys were grown w
Stem cell exhaustion and its role in healthy aging
2025-02-03 - 2025-02
What is stem cell exhaustion?
Stem cell exhaustion is the gradual decline in the function and regenerative potential of adult stem cells over time. In various tissues, the upkeep of homeostasis and the capacity to regenerate after injury depend on tissue-specific adult stem cells. These stem cells typically follow tissue-specific differentiation patterns. Their ability to alternate between states of rest (quiescence) and active proliferation is crucial for their survival and for preserving normal physiological function and regenerative capabilities. (1) Adult tissue-specific stem cells exhibit an extraordinary degree of plasticity as they transit through cellular states from a quiescent to an activated stem cell state and then revert to their original quiescent state. (2) To protect against infection and promote healing, the usual homeostatic signals that regulate transition through quiescent and active states – referred to as the ‘milieu intérieur’ by Claude Bernard in 1865 – must be bypassed in ways that are still not fully understood. (2)
Quiescence is not a passive condition; instead, like the differentiated state, it requires ongoing active regulation to be sustained. Such transitional capacity, however, is largely lost in aging, as stem cells fail to survive or properly regulate quiescence, self-renewal, and proliferation, a state called stem cell exhaustion. (3) These observations support the stem cell theory of aging, which suggests that aging results from the inability of tissue-specific stem cells to replenish tissues with functional differentiated cells that sustain tissue function. They also pave the way for a new era of research into the stem cell aging, which may offer therapeutic potential. (4) Key Features of stem cell exhaustion are reduced proliferation, impaired differentiation, accumulative DNA damage, senescence, and altered niche.
What do we know about the causes of stem cell exhaustion?
In many aging tissues, the stem cells reduced regenerative ability comes from both intrinsic changes within the stem cells themselves and extrinsic alterations in the stem cell niche microenvironment. Central to intrinsic factors, the transcriptional and epigenetic misregulation of gene pathways in aging stem cells leads to alterations in their proliferation and differentiation in vivo. For example, in muscle, quiescent stem cells possess a permissive chromatin state in which few genes are epigenetically repressed by repressive histone mark H3K27me3, and many genes encoding regulators that specify non-myogenic lineages are demarcated by bivalent domains at their transcription start sites (TSSs). During aging, there is a global increase in H3K27me3 across the genome. (5)
As these epigenetic changes accumulate with age, they may contribute to a functional decline in quiescent muscle stem cells (MuSCs). Alterations of the chromatin landscape have also been seen in hair follicle stem cells (HF-SCs). Specifically, reduced open chromati
How healthy stem cells turn into oral cancer
2025-02-04 - 2025-02
Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise. Now, researchers at University of California San Diego have discovered how healthy stem cells are transformed into cancer stem cells in the earliest stages of the disease.
Oral cancer—also known as head and neck squamous cell carcinoma—affects the mouth, throat, nose, sinuses and voice box. The cancer takes root in epithelial cells, the top layer of cells lining these cavities. Around 30% of oral cancer cases are caused by human papillomavirus (HPV).
By activating a signaling protein called YAP (yes-associated protein, a transcription factor normally involved in stem cell maintenance and growth promotion) in combination with HPV oncogenes (genes that inhibit the normal suppression of tumor growth), the researchers triggered a cascade of cellular and molecular changes that reprogrammed normal stem cells into cancer cells in a mouse model.
The researchers used several state-of-the-art technologies to trace the progression of changes that transformed healthy stem cells to cancer stem cells at the resolution of the single cell.
The study, published in Nature Communications, is the first to use technologies such as cell tracing (marking cells to follow their proliferation through time) and multi-omics (analyzing molecular data from genomics, RNA transcription, protein expression, epigenetic changes and cellular metabolites to understand disease development) at the resolution of single cells to follow the real-time progression of these changes in a living organism.
"We can understand precisely how you go from one cell state to another cell state and identify the very, very early events in tumor initiation rather than the final state of cancer," said senior author J. Silvio Gutkind, Ph.D., Distinguished Professor and chair at UC San Diego School of Medicine Department of Pharmacology, and associate director for basic science at UC San Diego Moores Cancer Center.
The researchers found that activating YAP in combination with HPV oncogenes:
resulted in invasive cancer within just 10 days;
caused a loss of normal cell identity by halting normal cell differentiation, leading to the acquisition of a more mobile and invasive state;
promoted unrestrained cell proliferation by promoting epigenetic changes and stimulating pathways related to carcinoma cell growth, survival, and migration; and
resulted in the secretion of factors that recruited and reprogrammed immune cells to break down tissue barriers, evade immune detection, and facilitate tumor cell invasion.
Gutkind says the next step is to use the same technologies to understand what leads to the progression of normal stem cells to cancer stem cells in HPV-negative oral cancers, which are most common in smokers and older patients. His team is also exploring whether recently developed drugs that block YAP function may provid
Lifestyle Expert Recommends 8 Top Foods To Boost Stem Cells For Better Recovery And Health
2025-02-06 - 2025-02
A strong immune system is key to defending the body against harmful germs that can cause various diseases. But don't worry – lifestyle coach Luke Coutinho has a solution. In an Instagram post, he encourages everyone to create their own natural pharmacy using everyday kitchen ingredients. He shares a video highlighting the top foods that can boost specific bodily functions and enhance overall health.
Luke Coutinho begins his post by explaining stem cells, describing them as “special cells that each of us are gifted with,” functioning as the “body's ultimate repair team.” According to him, stem cells are unique because they “have the ability to transform into any type of cell your body needs – from muscle cells to skin cells to nerve cells.” He further emphasizes their critical role in repairing and regenerating damaged tissues and organs, reducing inflammation, enhancing recovery after injuries, supporting tissue regeneration and accelerating healing after surgery or intense physical activity.
Following this, Luke Coutinho shares a list of eight foods scientifically backed to fuel stem cells and maximize overall health.
8 Foods scientifically backed to fuel stem cells & boost health
1. Broccoli & cruciferous vegetables
These vegetables contain compounds that help neutralize toxins and create the perfect environment for your cells to thrive.
2. Blueberries/ Indian gooseberries (amla)
Packed with anthocyanins, these berries protect stem cells from oxidative damage and promote their renewal.
3. Leafy greens
Rich in folate, leafy greens support stem cell differentiation and regeneration.
4. Turmeric
The curcumin in turmeric reduces inflammation and promotes stem cell proliferation and differentiation.
5. Pomegranate
The ellagic acid in pomegranate supports stem cell health by reducing oxidative stress and enhancing regeneration.
6. Bone broth
Collagen and amino acids in bone broth provide essential building blocks for stem cell regeneration and tissue repair.
7. Ginger
Gingerol in ginger activates stem cells for tissue repair and regeneration.
8. Mushrooms
Beta-glucans in these mushrooms enhance stem cell activity and boost immune function.
“These foods are no magic foods—they work synergistically with overall lifestyle changes to optimize your body's natural repair and regeneration processes. Add them to your daily routine, and unlock your body's natural healing power like never before,” Luke Coutinho writes in his caption.
He also adds a disclaimer – “These foods complement your overall health, but they are not a substitute for medical treatment. These foods are no magic foods, and the focus has to always be on overall lifestyle changes. Always consult with your healthcare provider before making dietary changes.”
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor fo
Stem Cells in the Brain Use Childlike Signals to Trigger Regeneration
2025-02-08 - 2025-02
Summary: Scientists have discovered that neural stem cells (NSCs) receive constant feedback from their daughter cells, influencing whether they remain dormant or activate to form new neurons and glia. This parent-child relationship helps regulate brain regeneration and repair.
The study also reveals that calcium signaling plays a key role in how NSCs decode multiple signals from their environment. If NSCs produce only a few daughter cells, they activate; if they produce many, they stay dormant.
These findings challenge previous assumptions that NSCs function independently and open new avenues for treating neurodevelopmental disorders. Future research will explore how these processes change in aging and disease.
Neural Stem Cell Feedback: NSCs stay dormant or activate based on signals from their own daughter cells.
Calcium’s Role: Calcium signaling enables NSCs to integrate and decode multiple brain signals.
Therapeutic Potential: Understanding NSC activation could lead to treatments for neurological disorders and brain injury repair.
Source: University of Ottawa
A University of Ottawa neuroscientist has led a Canadian research team to reveal important new insights into the activation dynamics of neural stem cells (NSCs). These are the stem cells that build our central nervous systems and the self-renewing.
The collaborative team led by the University of Ottawa’s Dr. Armen Saghatelyan aimed to shed light on how neural stem cells integrate a multitude of signals from different cell types in the brain – and how they decode these signals.
These are big questions because how NSCs react to signals in their cellular environment controls whether they remain in their dormant, non-dividing state known as “quiescence” or if they get activated to grow and divide, generating new neurons and glia in the process.
The reported findings, published today in Cell Stem Cell, will certainly be of deep interest to scientists studying a range of adult neurological diseases and aging. In the neural landscape, rousing NSCs from dormancy, where they conserve resources and energy, is key for neural regeneration and brain injury repair.
“These data make it possible to understand better how NSCs can be activated to generate more neurons and glia in order to counteract different neurological disorders and aging. We are currently studying NSCs’ responses for some of these conditions,” says Dr. Saghatelyan, Canada Research Chair in Postnatal Neurogenesis and the new publication’s senior author. (Neurogenesis is the process by which new neurons are formed in the brain.)
Cellular “parent-child” relationship
One avenue of new insight focuses on how stem cells wrap around progeny called “daughter” cells – genetically identical cells created after a parent cell divides.
The team discovered that neural stem cells are in fact receiving constant feedback from their chatty daughter cells. Dr. Saghatelyan likens this to a “parent-child relationship” i
Useful Links
Subscribe Now
